ArticleSleep medicine: X2026
Effect of diamine oxidase (DAO) enzyme dietary supplementation in subjects with insomnia symptoms and single nucleotide polymorphisms of the
Article in Sleep medicine: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This exploratory study was designed to assess the effect of a diamine oxidase (DAO) enzyme supplement on insomnia symptoms in patients with alterations of the Methods: Prospective randomized, double-blind placebo-controlled study. Patients were randomized (1:1:1:1) to 28-day supplementation with the DAO product (12.6 mg/day) or placebo. The Insomnia Severity Index (ISI) and the Pittsburg Sleep Quality Index (PSQI) were completed. Results: We studied 101 patients (DAO group, n = 50; placebo, n = 51) (73.4 % women, mean age 48.3 years). Decreases in ISI scores were similar in both groups, but severe insomnia at day 28 was higher in the placebo group (5.9 % vs. 2 %). Improvement of PSQI at day 28 was higher in the DAO group (mean [SD] change -1.62 [3.45] vs. -1.47 [3.21]). Improvements of at least 1 point of PSQI in various subscales were higher in the DAO group. Also, in the DAO group and the once-daily regimen, sleep efficiency and use of sleep medication showed significant improvements vs. baseline (mean change of -0.71 [1.43], Conclusions: In this exploratory study, the use of a DAO supplement for 28 days improved insomnia symptoms in the presence of genetic variants of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.